OBJECTIVE: It was previously shown that higher concentrations of myo-inositol in human follicular fluid improve oocyte and embryo quality, whereas D-chiro-inositol seems to worsen oocyte quality and ovarian response in polycystic ovary syndrome patients. Our study was the first one aiming to test whether different myo-inositol and D-chiro-inositol concentration in follicular fluids correlate with blastocyst quality in healthy young women. PATIENTS AND METHODS: Eight egg donors and eleven couples undergoing in vitro fertilization, were involved in a prospective observational study. Myo-inositol/D-chiro-inositol ratio was calculated in the follicular fluids and associated with different blastocyst grades. Donors were homogeneous and followed the same standard stimulation protocol. RESULTS: The ratio between myo-inositol and D-chiro-inositol was significantly higher in the specimens rated as good quality blastocysts, compared to those rated as poor-quality blastocysts. In this study, almost all the transferred blastocysts were graded as good quality and were correlated to lower D-chiro-inositol content in the follicular fluid; the implantation rate and pregnancy rate were satisfying. Our data suggest that the reduction of such ratio in follicular fluid seems to play a negative role in follicular development. CONCLUSIONS: We found a correlation between myo-inositol/D-chiro-inositol ratio in follicular fluid and blastocyst quality. The value of this ratio may represent a new biomarker for estimating the good features of blastocysts, and a prognostic factor of embryo implantation and pregnancy success. Moreover, the pre-treatment with myo-inositol in women undergoing in vitro fertilization (IVF) may improve oocyte quality and ART outcome. CLINICAL TRIAL REGISTRATION NUMBER: NCT03055442 (ClinicalTrials.gov registry).
OBJECTIVE: It was previously shown that higher concentrations of myo-inositol in human follicular fluid improve oocyte and embryo quality, whereas D-chiro-inositol seems to worsen oocyte quality and ovarian response in polycystic ovary syndromepatients. Our study was the first one aiming to test whether different myo-inositol and D-chiro-inositol concentration in follicular fluids correlate with blastocyst quality in healthy young women. PATIENTS AND METHODS: Eight egg donors and eleven couples undergoing in vitro fertilization, were involved in a prospective observational study. Myo-inositol/D-chiro-inositol ratio was calculated in the follicular fluids and associated with different blastocyst grades. Donors were homogeneous and followed the same standard stimulation protocol. RESULTS: The ratio between myo-inositol and D-chiro-inositol was significantly higher in the specimens rated as good quality blastocysts, compared to those rated as poor-quality blastocysts. In this study, almost all the transferred blastocysts were graded as good quality and were correlated to lower D-chiro-inositol content in the follicular fluid; the implantation rate and pregnancy rate were satisfying. Our data suggest that the reduction of such ratio in follicular fluid seems to play a negative role in follicular development. CONCLUSIONS: We found a correlation between myo-inositol/D-chiro-inositol ratio in follicular fluid and blastocyst quality. The value of this ratio may represent a new biomarker for estimating the good features of blastocysts, and a prognostic factor of embryo implantation and pregnancy success. Moreover, the pre-treatment with myo-inositol in women undergoing in vitro fertilization (IVF) may improve oocyte quality and ART outcome. CLINICAL TRIAL REGISTRATION NUMBER: NCT03055442 (ClinicalTrials.gov registry).
Authors: Simona Dinicola; Vittorio Unfer; Fabio Facchinetti; Christophe O Soulage; Nicholas D Greene; Mariano Bizzarri; Antonio Simone Laganà; Shiao-Yng Chan; Arturo Bevilacqua; Lali Pkhaladze; Salvatore Benvenga; Annarita Stringaro; Daniele Barbaro; Marialuisa Appetecchia; Cesare Aragona; Maria Salomè Bezerra Espinola; Tonino Cantelmi; Pietro Cavalli; Tony T Chiu; Andrew J Copp; Rosario D'Anna; Didier Dewailly; Cherubino Di Lorenzo; Evanthia Diamanti-Kandarakis; Imelda Hernández Marín; Moshe Hod; Zdravko Kamenov; Eleni Kandaraki; Giovanni Monastra; Mario Montanino Oliva; John E Nestler; Maurizio Nordio; Ali C Ozay; Olga Papalou; Giuseppina Porcaro; Nikos Prapas; Scott Roseff; Monica Vazquez-Levin; Ivana Vucenik; Artur Wdowiak Journal: Int J Mol Sci Date: 2021-09-30 Impact factor: 5.923